Browsing: Headwinds

On October 01, 2026, Nike Inc (NYSE: NKE) reported a 4% year-over-year decline in overall sales, driven primarily by a 22% plunge in its Greater China segment and weakness in e-commerce channels. The mixed fiscal first-quarter results and a cautious outlook for fiscal year 2027 triggered a selloff in after-hours trading.

The past few years have been challenging for Pfizer (NYSE: PFE). The company has faced macroeconomic problems, significantly lower sales from its coronavirus portfolio, and looming patent cliffs, including for its best-selling drug, the anticoagulant Eliquis. However Pfizer’s headwinds are easing. Is he right?

Housing starts fell in July as economic uncertainty, rising construction costs, labor shortages and elevated financing expenses continued to challenge builders.